9-benzyl-2-(2-methoxy-ethoxy)-9H-purin-6-ylamine | 226908-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-benzyl-2-(2-methoxy-ethoxy)-9H-purin-6-ylamine
• 英文别名: 6-Amino-9-benzyl-2-(2-methoxyethoxy)purine；9-benzyl-2-(2-methoxyethoxy)purin-6-amine
• CAS: 226908-75-4
• 化学式: C₁₅H₁₇N₅O₂
• 分子量: 299.332
• InChiKey: LULPRDHICBDHGB-UHFFFAOYSA-N

物化性质

• 沸点：
  555.5±60.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  88.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  9-benzyl-2-(2-methoxy-ethoxy)-9H-purin-6-ylamine 在 溴 作用下， 以 二氯甲烷 为溶剂， 生成 6-Amino-9-benzyl-8-bromo-2-(2-methoxyethoxy)purine
  参考文献：
  名称：

  Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities

  摘要：

  In order to create novel compounds which possess potent interferon (IFN) inducing activities with excellent oral bioavailabilities, a series of 8-hydroxyadenines, which have various alkoxy or alkylthio moieties at the adenine C(2)-position, were synthesized and evaluated. The introduction of hydrophobic groups was not considered to be effective for potentiating the IFN-inducing activity, but several compounds having hydrophilic groups were effective. Among the compounds tested, compound 13f induced IFN from the dosage of 0.03 mg/kg, which was approximately 100-fold more potent than that of Imiquimod, and showed an excellent oral bioavailability (F = 40%) which was 10-fold improved over 5, a lead compound (F = 4%). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.008
• 作为产物：
  描述：

  9-苄基-2-氯腺嘌呤 在 sodium 作用下， 以 乙二醇甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 以71%的产率得到9-benzyl-2-(2-methoxy-ethoxy)-9H-purin-6-ylamine
  参考文献：
  名称：

  Heterocyclic compounds

  摘要：

  本发明涉及以下通式（I）的杂环化合物：其中X是硫原子、氧原子或—NR3—（R3可能通过氮原子与R1形成杂环环或取代杂环环），R1是烷基、取代烷基、芳基、取代芳基、杂环基或取代杂环基，R2是氢原子、卤原子等；或其药学上可接受的盐和干扰素诱导剂、抗病毒剂、抗癌剂和免疫性疾病治疗剂，包括化合物（I）或其药学上可接受的盐作为活性成分。

  公开号：

  US06329381B1

文献信息

• Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
  申请人：Averett R. Devron

  公开号：US20050054590A1

  公开（公告）日：2005-03-10

  This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.

  这项发明涉及使用Toll样受体（TLR）7配体及其前药治疗或预防哺乳动物体内的丙型肝炎病毒感染的方法。更具体地，这项发明涉及口服给予一种或多种TLR7配体前药的治疗有效量，用于治疗或预防丙型肝炎病毒感染。将这些TLR7免疫调节配体及其前药口服给哺乳动物可提供治疗有效量并减少不良副作用。
• ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS
  申请人：Averett Devron R.

  公开号：US20090298863A1

  公开（公告）日：2009-12-03

  This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.

  本发明涉及使用Toll样受体(TLR)7配体及其前药治疗或预防哺乳动物的丙型肝炎病毒感染的方法。更具体地说，本发明涉及口服治疗丙型肝炎病毒感染的一种或多种TLR7配体前药的治疗剂量的方法。将这些TLR7免疫调节配体及其前药口服给哺乳动物，可提供治疗有效量和减少不良副作用。
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1035123A1

  公开（公告）日：2000-09-13

  The present invention relates to a heterocyclic compound of the following general formula (I): wherein X is sulfur atom, oxygen atom or -NR3- (R3 may form a heterocyclic ring or a substituted heterocyclic ring with R1 via the nitrogen atom), R1 is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, and R2 is hydrogen atom, halogen atom etc.; or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.

  本发明涉及以下通式(I)的杂环化合物： 其中 X 是硫原子、氧原子或-NR3-（R3 可通过氮原子与 R1 形成杂环或取代的杂环）、 R1 是烷基、取代的烷基、芳基、取代的芳基、杂环基或取代的杂环基，以及 R2 是氢原子、卤素原子等； 或其药学上可接受的盐，以及干扰素诱导剂、抗病毒剂、抗癌剂和以化合物（I）或其药学上可接受的盐为活性成分的免疫疾病治疗剂。
• Purine analogs
  申请人：The Regents Of the University of California

  公开号：EP2700638A1

  公开（公告）日：2014-02-26

  The present invention provides a new patentable class of purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.

  本发明提供了一类新的可申请专利的嘌呤类似物化合物以及使用它们的组合物和方法，例如，用于预防或治疗人类和非人类动物的各种疾病和失调。
• TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C
  申请人：Anadys Pharmaceuticals, Inc.

  公开号：EP1667694B1

  公开（公告）日：2010-04-28